Impact of Direct to Consumer Genetic Testing
Impact of Direct to Consumer Genetic Testing
批准号:
7987948
负责人:
Robert C. Green
金额:
$41.1万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-26 至 2011-04-01
关键词:
AddressAgeAllyAlzheimer&aposs DiseaseAreaArthritisAuthorization documentationBehaviorBenefits and RisksBioethicsBreastCharacteristicsChronic DiseaseClinicalCommunicationComplexComprehensionDataData CollectionDiabetes MellitusDisclosureDiscriminationDiseaseDistressEducationEmploymentEthicsFamilyFamily health statusFamily history ofFamily memberFemaleFrightFundingGeneticGenetic CounselingGenetic Predisposition to DiseaseGenetic RiskGenetic screening methodGenomeGenomicsGenus ColaGleanHealthHealth CommunicationHealth PersonnelHealth PsychologyHealth StatusHealth behaviorHealth educationHeart DiseasesIncomeIndustryInsuranceInternetLawsLungMalignant neoplasm of prostateMedicineMotivationNatureParticipantPersonal Genetic InformationPoliciesPopulationProceduresPsychological ImpactPublic HealthRecommendationResearchResearch Project GrantsRespondentRiskSalesSamplingServicesSurveysTest ResultTestingTimeTranslatingbasebehavioral healthdemographicsdesigndisorder preventiondisorder riskethical legal social implicationexperiencegenetic risk factorimprovedinterestlifestyle factorsliteracymembermiddle agepsychologicpublic health relevanceresponserisk perception
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The rapid identification of genetic risk factors for common, complex diseases poses great opportunities and challenges for public health. Genetic information is increasingly being utilized as part of commercial efforts, including direct-to-consumer (DTC) genetic testing to provide risk information on common diseases to consumers. Very few empirical data have been gathered to understand the characteristics of DTC test consumers, the psychological, behavioral and health impact, and the ethical, legal and social issues associated with DTC services. In the proposed research, we will survey users of the two leading US companies providing DTC genetic testing (23andMe and Navigenics) regarding their response to genetic tests for common diseases of interest, including heart disease, diabetes, Alzheimer's disease, arthritis, and breast, colon, lung and prostate cancers. Each company now has thousands of customers and each anticipates extensive sales in coming years. Each has agreed to allow our group to survey consumers using third-party data collection and analysis procedures that will enable an independent consideration of the benefits and risks of DTC testing in this format. The companies have also agreed to provide genetic test information (with respondents' permission) for analyses. A total of 1000 consumers (500 from each company) will be surveyed via the Internet before receipt of genetic test results, and we will survey this sample again at 1-2 weeks and six months following receipt of results. To carry out the proposed research, we have assembled an interdisciplinary team of experts with backgrounds in medicine, genetic testing policy and practice, health communication, genetic counseling, health psychology, health law, bioethics and web survey design. Many team members have collaborated on prior, related ELSI-funded research. Our aims are as follows: 1) to describe who seeks genetic testing and why, collecting information on demographics, motivations for seeking testing, and understanding of genetics; 2) to describe the impact of DTC genetic testing, including psychological impact, risk perceptions and comprehension, and personal utility of services; and 3) to assess what consumers do with their genetic information in the domains of health behaviors, insurance changes, information seeking, and communication with family and health care providers. This study will produce results that can be translated into recommendations to guide practice and policy in this rapidly emerging area.
PUBLIC HEALTH RELEVANCE: Genetic information is increasingly being utilized as part of commercial efforts, including direct-to-consumer (DTC) genetic testing to provide risk information on common diseases to consumers. We will survey customers of the two leading DTC genetic test services in the U.S., using independent third party data collection and analysis to provide data on who is ordering these tests and why, and what its benefits and risks may be. This study will produce results that can be translated into recommendations to guide practice and policy in this rapidly emerging area.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants
-
批准号:10652609
-
项目类别:
-
资助金额:$123.8万
-
财政年份:2021
-
负责人:Robert C. Green
-
依托单位:
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants
-
批准号:10442366
-
项目类别:
-
资助金额:$124.51万
-
财政年份:2021
-
负责人:Robert C. Green
-
依托单位:
Experiences and Outcomes in Early Adopters of Predispositional Sequencing
-
批准号:9789918
-
项目类别:
-
资助金额:$76.11万
-
财政年份:2018
-
负责人:Robert C. Green
-
依托单位:
Experiences and Outcomes in Early Adopters of Predispositional Sequencing
-
批准号:9980970
-
项目类别:
-
资助金额:$80.0万
-
财政年份:2018
-
负责人:Robert C. Green
-
依托单位:
Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals
-
批准号:9518218
-
项目类别:
-
资助金额:$11.45万
-
财政年份:2015
-
负责人:Robert C. Green
-
依托单位:
Integration of Whole Genome Sequencing into Clinical Medicine
-
批准号:8914756
-
项目类别:
-
资助金额:$15.45万
-
财政年份:2011
-
负责人:Robert C. Green
-
依托单位:
Integration of Whole Genome Sequencing into Clinical Medicine
-
批准号:8826154
-
项目类别:
-
资助金额:$237.06万
-
财政年份:2011
-
负责人:Robert C. Green
-
依托单位:
Integration of Whole Genome Sequencing into Clinical Medicine
-
批准号:8236471
-
项目类别:
-
资助金额:$241.08万
-
财政年份:2011
-
负责人:Robert C. Green
-
依托单位:
Integration of Whole Genome Sequencing into Clinical Medicine
-
批准号:9173270
-
项目类别:
-
资助金额:$213.26万
-
财政年份:2011
-
负责人:Robert C. Green
-
依托单位:
Integration of Whole Genome Sequencing into Clinical Medicine
-
批准号:8914780
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2011
-
负责人:Robert C. Green
-
依托单位:
Integration of Whole Genome Sequencing into Clinical Medicine
-
批准号:8586322
-
项目类别:
-
资助金额:$219.54万
-
财政年份:2011
-
负责人:Robert C. Green
-
依托单位:
Integration of Whole Genome Sequencing into Clinical Medicine
-
批准号:8393216
-
项目类别:
-
资助金额:$220.03万
-
财政年份:2011
-
负责人:Robert C. Green
-
依托单位:
Impact of Direct to Consumer Genetic Testing
-
批准号:8147863
-
项目类别:
-
资助金额:$36.82万
-
财政年份:2010
-
负责人:Robert C. Green
-
依托单位:
Impact of Direct to Consumer Genetic Testing
-
批准号:8334094
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2010
-
负责人:Robert C. Green
-
依托单位:
MPC-7869 MEASURE OF COGNITION, ACTIVITIES MILD DEMENTIA OF THE ALZHEIMER'S TYPE
-
批准号:7606297
-
项目类别:
-
资助金额:$0.17万
-
财政年份:2007
-
负责人:Robert C. Green
-
依托单位:
SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE
-
批准号:7606230
-
项目类别:
-
资助金额:$0.69万
-
财政年份:2007
-
负责人:Robert C. Green
-
依托单位:
HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE IN ALZHEIMER'S DISEASE
-
批准号:7606235
-
项目类别:
-
资助金额:$0.31万
-
财政年份:2007
-
负责人:Robert C. Green
-
依托单位:
STUDY OF LEUPROLIDE ACETATE DEPOT IN THE TREATMENT OF AD IN MEN
-
批准号:7606250
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2007
-
负责人:Robert C. Green
-
依托单位:
ASSESSMENT MEASURES FOR PRIMARY PREVENTION TRIALS IN ALZHEIMERS DISEASE
-
批准号:7606223
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2007
-
负责人:Robert C. Green
-
依托单位:
AGING AND ALZHEIMER'S DISEASE BIOSAMPLE REPOSITORY
-
批准号:7606237
-
项目类别:
-
资助金额:$1.04万
-
财政年份:2007
-
负责人:Robert C. Green
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: